Aiming to cover the landscape of hyperoxaluria – overproduction of oxalate in the kidneys, which can lead not only to painful stones but also, in other forms, complications as serious as end-stage renal disease – Allena Pharmaceuticals Inc. raised $25 million in a series B financing.